Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.52 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 5/20 | 0.48 |
| ▸ | MME | P08473 | 5/20 | 0.48 |
| ▸ | CPA1 | P15085 | 3/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22285670 | 1.00 | ITGB3 (0.52) | ITGB3ITGA2BGPR34ACEMME | |
| SCHEMBL22302993 | 0.86 | NLRP3 (0.59) | ACACBNLRP3 | |
| SCHEMBL22338787 | 0.86 | NLRP3 (0.59) | ACACBNLRP3 | |
| SCHEMBL7292657 | 0.85 | CTSS (0.56) | ITGB3ITGA2BGPR34ACEMME | |
| SCHEMBL5435245 | 0.85 | CTSS (0.56) | ITGB3ITGA2BGPR34ACEMME | |
| SCHEMBL5435243 | 0.85 | CTSS (0.56) | ITGB3ITGA2BGPR34ACEMME | |
| SCHEMBL9258153 | 0.82 | MME (0.47) | ITGB3ITGA2BGPR34ACEMME | |
| SCHEMBL22338716 | 0.82 | ACE (0.50) | ITGB3ITGA2BACEMMECPA1 | |
| SCHEMBL4179483 | 0.82 | FOLH1 (0.62) | ITGB3ITGA2BACEMMECPA1 | |
| SCHEMBL4187321 | 0.82 | FOLH1 (0.62) | ITGB3ITGA2BACEMMECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | DICE MOLECULES SV, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-3921038-A1 | IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163554-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | DICE MOLECULES SV, INC. | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | IL17A, IL2, IL15 | ITGB3 487/4885ITGA2B 411/4885GPR34 1681/4885 |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | IL17A, IL2, IL15 | ITGB3 487/4885ITGA2B 411/4885GPR34 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.